Eli Lilly CDR (CAD Hedged)
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1200
- Registration Number
- NCT06653153
- Locations
- ๐บ๐ธ
Parkway Medical Center, Birmingham, Alabama, United States
๐บ๐ธMD First Research - Chandler, Chandler, Arizona, United States
๐บ๐ธCare Access - 801 South Power Road, Mesa, Mesa, Arizona, United States
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT06649045
- Locations
- ๐บ๐ธ
Ark Clinical Research, Long Beach, California, United States
๐บ๐ธArk Clinical Research, Long Beach, California, United States
๐บ๐ธPeninsula Research Associates, Rolling Hills Estates, California, United States
A Study of [14C]-LY3866288 in Healthy Participants
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT06644378
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT06643728
- Locations
- ๐บ๐ธ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
๐บ๐ธCentral Research Associates, Birmingham, Alabama, United States
๐บ๐ธDiablo Clinical Research, Inc., Walnut Creek, California, United States
A Study of LY3866288 in Healthy Participants
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT06641037
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT06635057
- Locations
- ๐ธ๐ฆ
King Fahad Armed Forces, Jeddah, Al Andalus, Saudi Arabia
๐ธ๐ฆSaudi Airlines Medical services, Jeddah, AlKhalidiyyah, Saudi Arabia
๐ธ๐ฆDr Sulaiman Al Habib Medical Group-Olaya, Riyadh, Alolaya, Saudi Arabia
A study to characterise the safety, tolerability and efficacy of the pan-KRAS inhibitor LY4066434 in participants with KRAS mutant advanced solid tumors.
- Conditions
- KRAS mutant solid tumors.
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Eli Lilly & Co.
- Target Recruit Count
- 353
- Registration Number
- 2024-516733-12-00
- Locations
- ๐ง๐ช
Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Belgium
๐ง๐ชUniversitair Ziekenhuis Gent, Gent, Belgium
๐ง๐ชInstitut Jules Bordet, Anderlecht, Belgium
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 230
- Registration Number
- NCT06606106
- Locations
- ๐บ๐ธ
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
๐บ๐ธFortrea Clinical Research Unit, Dallas, Texas, United States
๐บ๐ธClinical Pharmacology of Miami, Miami, Florida, United States
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT06598631
- Locations
- ๐บ๐ธ
Rancho Research Institute, Downey, California, United States
๐บ๐ธSouthwest Nephrology Associates, Evergreen Park, Illinois, United States
๐บ๐ธNephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale, Hinsdale, Illinois, United States
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06603571
- Locations
- ๐บ๐ธ
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
๐บ๐ธHOPE Research Institute, Phoenix, Arizona, United States
๐บ๐ธHeadlands Research - Scottsdale, Scottsdale, Arizona, United States